Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent

Clinical Cancer Research

Volumn 3, Issue 3, 1997, Pages 401-407

  Rowinsky, Eric K ^a,b   Long, G Scott ^a   Noe, Dennis A ^a   Grochow, Louise B ^a   Bowling, M K ^a   Sartorius, Susan E ^a   Donehower, Ross C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIVOBULIN ISETHIONATE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBAMATES; CENTRAL NERVOUS SYSTEM DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PYRAZINES; PYRIDINES; THROMBOCYTOPENIA;

EID: 0030887268     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Temple, C., Jr., Wheeler, G. P., Elliot, R. D., Rose, J. D., Comber, R. N., and Montgomery, J. A. New anticancer agents: synthesis of 1,2-dihydropyrido[3,4-b]pyrazines: structure-activity relationships. J. Med. Chem., 26: 91-95, 1992.
2. Wheeler, G. P., Bowdon, B. J., Werline, J. A., Adamson, D. J., and Temple, C. G. Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,2-dihdryo-3-[(N-methylanilino)methyl]-pyrido[3,4-b]pyrazin-7- ylcarbamate (NSC 181928). Cancer Res., 42: 791-798, 1982.
3. Wheeler, G. P., Bowdon, B. J., Temple, C., Jr., Adamson, D. J., and Webster, J. Biological effects and structure-activity relationships of l,2-dihydropyrido[3,4-b]pyrazines. Cancer Res., 43: 3567-3575, 1983.
4. Bowdon, B. J., Waud, W. R., Wheeler, G. P., Hain, R. H., Dansby, L., and Temple, C. G. Comparison of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis. Cancer Res., 47: 1621-1626, 1987.
5. Temple, C., Jr., and Rener, G. A. New anticancer agents: chiral isomers of ethyl (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido-[3,4-b]pyrazin-7-yl)-carbamate. J. Med. Chem., 32: 2089-2092, 1989.
6. de Ines, C., Leynadier, D., Barasoain, I., Peyrot, V., Garcia, P., Briand, C., Rener, G. A., and Temple, C., Jr. Inhibition of microtubules and cell cycle arrest by a new l-deaza-7,8-dihydropteridine antitumor drug CI-980, and by its chiral isomer, NSC 613863. Cancer Res., 54: 75-84, 1994.
7. Waud, W. R., Leopold, W. R., Elliot, W. L., Dykes, D. J., Laster, W. R., Jr., Temple, C. G., Jr., Harrison, S. D., Jr., and Griswold, D. P., Jr. Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate hydrate (NSC 370147) against selected tumor systems in culture and in mice. Cancer Res., 50: 3239-3244, 1990.
8. Park-Davis Pharmaceutical Research Division, Warner-Lambert Company. Investigator's Brochure. 1990.
9. Sklarin, N. T., Benson, L., Roca, J., Einzig, A. I., Wiernik, P. H., Whitfield, L. R., Lathia, C., Kowal, C., and Grove, W. Phase I study of CI-980: 24-h infusion schedule. Proc. Am. Soc. Clin. Oncol., 14: 479, 1995.
10. Natale, R., Waterhouse, D., Grove, W., Whitfield, L. R., Brodfuehrer, J., and Kowal, C. Phase I clinical and pharmacokinetic trial of CI-980, a novel mitotic inhibitor. Proc. Am. Soc. Clin. Oncol., 11: 118, 1992.
11. Division of Cancer Treatment, National Cancer Institute. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD: National Cancer Institute, 1988.
12. Folstein, M. F., Folstein, S. E., and McHugh, P. R. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res., 12: 189-198, 1975.
13. Bullen, W. W., Whitfield, L. R., Walter, G. A., and Brodfuehrer, J. I. High-performance liquid Chromatographic assay for CI-980, a novel 1-deaza-7,8-dihydropteridine anticancer agent, in human plasma and urine. J. Chromatogr. B. Biomed. Appl., 668: 141-151, 1995.
14. Sacken, D. L. Podophyllotoxin, steganacin, and combrestatin: natural products that bind at the colchicine binding site of tubulin. Pharmacol. & Ther., 59: 163-228, 1993.
15. Griswold, D. P., Temple, C. G., Trader, M. W., Leopold, W. R., Laster, W. R., and Dykes, D. J. Antitumor activity of a novel 1,2-dihydropyrido[3,4-b]pyrazine in preclinical drug-sensitive and -resistant tumors. Proc. Am. Assoc. Cancer Res., 27: 306, 1986.
16. Pazdur, R., Diaz-Canton, E., Meyers, C., Abbruzzese, J., Patt, Y., Rivera, E., Touroutoglou, N., Edwards, K., Bready, B., and Ajani, J. A. Phase II trial of CI-980 in metastatic colorectal carcinoma patients. Proc. Am. Soc. Clin. Oncol., 14: 208, 1995.
17. Verschraegen, C. F., Kudelka, A. P., Edwards, C. L., Meyers, C. A., Conrad, C. A., Freedman, R. S., Gonzalez de Leon, C., Finnegan, M. B., Hord, M., Mante, R., Calayag, M., Grove, W., and Kavanagh, J. J. Phase II trial of CI-980 in advanced epithelial ovarian carcinoma. Proc. Am. Soc. Clin. Oncol., 14: 271, 1995.
18. Gutheil, J., Van Echo, D., Egorin, M., Panitch, H., Swallow, L., O'Hara, S., and Kearns, C. Phase I study of CI-980 in patients with refractory malignancies. Proc. Am. Assoc. Cancer Res., 37: 164, 1996.
19. MacDonald, J. R., and Pegg, D. G. Extravasation injury potential of CI-980, a novel synthetic mitotic inhibitor. Cancer Chemother. Pharmacol., 32: 365-367, 1993.